Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
-
First generic source for DR-TB drug linezolid eligible for procurement
Geneva, 18 June 2013 - The first affordable generic version of linezolid (600mg tablet), a drug used to treat drug-resistant tuberculosis (DR-TB), has been reviewed by the Global Fund Expert Review Panel*, and is now eligible for procurement under Global Fund grants to treat DR-TB. For parties interested in procuring the Hetero product outside of the Global Fund mechanism, the Expert Review Panel’s assessment provides an added level of quality assurance for the product.
Last updated 18 June 2013
www.msfaccess.org/content/first-generic-source-dr-tb-drug-linezolid-eligible-procurement -
MSF welcomes WHO guidelines on TB drug bedaquiline; but more work needed
Last updated 13 June 2013
www.msfaccess.org/content/msf-welcomes-who-guidelines-tb-drug-bedaquiline-more-work-needed -
MSF responds to TRIPS exclusion extension for least-developed countries
Geneva, 11 June 2013 - Ahead of a transition period that allows least-developed countries (LDC) to avoid introducing some intellectual property rules expiring this month, LDC members of the World Trade Organization (WTO) requested an extension that would enable them to remain exempt from implementing nearly all provisions of the TRIPS* agreement, including for pharmaceutical products, until they are no longer classified as ‘least-developed’.
Last updated 11 June 2013
www.msfaccess.org/content/msf-responds-trips-exclusion-extension-least-developed-countries -
MSF intervention on Global Vaccine Action Plan at 66th WHA
World Health Assembly 66; Agenda item 66/19: Global Vaccine Action Plan Intervention by Kate Elder, Médecins Sans Frontières Médecins Sans Frontières welcomes the focus on immunisation brought by the Decade of Vaccines.
Last updated 27 May 2013
www.msfaccess.org/content/msf-intervention-global-vaccine-action-plan-66th-wha -
MSF intervention on R&D Financing & Coordination at 66th WHA
WHO 66th World Health Assembly Agenda item 17.2: Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) Intervention by Katy Athersuch, Médecins Sans Frontières
Last updated 24 May 2013
www.msfaccess.org/content/msf-intervention-rd-financing-coordination-66th-wha -
MSF intervention on WHO reform at 66th World Health Assembly
WHO 66th World Health Assembly Agenda Item 11 - WHO ReformIntervention by Manica Balasegaram, Médecins Sans Frontières Thank you chair, The question of reform of WHO has been the subject of numerous discussions and papers since 2011.
Last updated 22 May 2013
www.msfaccess.org/content/msf-intervention-who-reform-66th-world-health-assembly -
Joint Letter to the 66th World Health Assembly: Follow-up of the report of the CEWG
On the opening of the 66th World Health Assembly, MSF along with other organisations and individuals, submitted a letter to the World Health Organization (WHO) and its Member States to "exercise leadership, ambition and innovative thinking in developing new paradigms to take forward the word of the Consultative Expert Working group on Research and Development (CEWG)". EXCERPT: "Distinguished Delegate,
Last updated 17 May 2013
www.msfaccess.org/content/joint-letter-66th-world-health-assembly-follow-report-cewg -
DNDi at ten: past success, future challenges
Since it was created in 2003, there is little doubt that the Drugs for Neglected Diseases initiative (DNDi) has been one of the most successful Product Development Partnerships (PDPs), with 6 new treatments delivered for 4 diseases in less than ten years. While these have been developed from existing or repurposed drugs, the achievement is tangible in that many of these treatments (like NECT, ASAQ fixed dose combination and SSG&PM) are being rolled out and scaled up in endemic countries where they are needed the most.
Last updated 16 May 2013
www.msfaccess.org/content/dndi-ten-past-success-future-challenges -
U.S. Penalises India for Promoting Access to Medicines Strategies by Placing it on Trade "Watch List"
The U.S. Trade Representative's decision to place India on its annual trade "Watch List" is a bully tactic being used to punish the country for taking steps to ensure access to affordable, lifesaving medicines and to prevent other developing countries from following similar strategies. By placing India on the Watch List in its annual Special 301 Report, the U.S. is disregarding the fact that India has acted within its rights under existing international trade rules and that its measures will increase access to medicines for millions.
Last updated 2 May 2013
www.msfaccess.org/content/us-penalises-india-promoting-access-medicines-strategies-placing-it-trade-watch-list -
MSF statement on GAVI's response to 'Dear GAVI' campaign
MSF launched the "Dear GAVI" campaign on 23 April to push for GAVI to extend its discounted prices on vaccines to MSF and other NGOs and humanitarian actors so that we can reach more of the most vulnerable children. In response, GAVI issued a statement and below is MSF's own response.
Last updated 24 April 2013
www.msfaccess.org/content/msf-statement-gavis-response-dear-gavi-campaign
